- Clinical Trials
- April 2024
- 70 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- December 2024
- 66 Pages
Global
From €3323EUR$3,495USD£2,791GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 92 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- November 2022
- 93 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 46 Pages
Global
From €1901EUR$2,000USD£1,597GBP

The Liver Failure Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs used to treat liver failure, a condition in which the liver is unable to perform its normal functions. These drugs are used to reduce the symptoms of liver failure, such as jaundice, ascites, and encephalopathy, as well as to prevent further damage to the liver. Commonly used drugs include diuretics, antibiotics, antivirals, and immunosuppressants.
The Liver Failure Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Other companies include AstraZeneca, Bayer, Novartis, and Sanofi. Show Less Read more